Technology
Technology
PeptoVac®
PeptoVac®
PeptoVac® is the platform technology for a target T-cell vaccine using a peptide epitope. After formulation, the target epitope is mixed with Nexavant II, specially designed for a potent T-cell activation. The mixture induces an epitope-specific T-cell response that leads to an anticancer effect or control of viral infection.
The improved anti-tumor effect by PeptoVac. C57bl/6 mice have inoculated IV with HPV expressing TC-1 tumor cells to induce the lung metastasized tumor. Each mouse was treated with PeptoVac containing a single HPV epitope post 7, 14, 21, and 28 days of tumor implanting. Tumor volume day survival was measured at indicated time points. The T-cell response was monitored on day 90. The tumor re-challenge was made on day 104.
Improved PeptoVac efficacy with a dual therapy. C57bl/6 mice have inoculated IV with HPV expressing TC-1 tumor cells to induce the lung metastasized tumor. Each mouse was treated with PeptoVac containing a single HPV epitope post 7, 13, 19, and 26 days of tumor implanting. Tumor volume day survival was measured at indicated time points. The combinational therapy with a know chemo-drug with PeptoVac and showed a complete response in all vaccinated mice.
Anticancer effect of PeptoVac against a brain cancer model. After a cancer cell line is implanted to brain, the therapeutic effect of vaccine was tested. Contrast to the moderate effect of PaptoVac alone, combination with a known chemo-drug shows a complete response in all the testing animals.
for T-cell activation
